Record-Breaking Price Movement
On 12 June 2026, Venus Remedies Ltd’s share price touched an intraday high of Rs.1799, representing a 4.81% increase during the trading session. The stock opened with a gap up of 3.34% and closed with a strong gain of 4.85%, outperforming the Sensex which rose by 1.86% on the same day. This price level also sets a new 52-week high, surpassing the previous peak and signalling strong investor confidence in the company’s fundamentals.
The stock has demonstrated consistent upward momentum, recording gains for three consecutive days and delivering a cumulative return of 9.7% over this period. Furthermore, Venus Remedies outperformed its sector by 1.78% on the day, underscoring its relative strength within the Pharmaceuticals & Biotechnology industry.
Long-Term Performance and Market Position
Venus Remedies Ltd’s stock has exhibited exceptional performance over multiple time horizons. Over the past year, the stock has generated a staggering return of 303.51%, vastly outperforming the Sensex’s decline of 7.94% during the same period. Year-to-date returns stand at 134.63%, compared to the Sensex’s negative 11.75%. The company’s three-year return of 673.54% and five-year return of 475.89% further highlight its sustained growth trajectory, far exceeding the broader market benchmarks.
Over a decade, Venus Remedies has delivered an extraordinary return of 2077.43%, dwarfing the Sensex’s 182.36% gain. This long-term outperformance reflects the company’s ability to maintain growth and profitability in a competitive sector.
Technical Indicators and Market Sentiment
The technical outlook for Venus Remedies Ltd remains bullish. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating strong upward momentum. Key technical indicators such as MACD, Bollinger Bands, KST, Dow Theory, and On-Balance Volume (OBV) all signal a positive trend on both weekly and monthly charts.
Immediate support is established at the 52-week low of Rs.417.65, while the stock has decisively broken through previous resistance levels, including the 20-day moving average at Rs.1293.20. The current price level near Rs.1799 represents a significant resistance breakthrough, reinforcing the bullish sentiment.
Financial Strength and Quality Metrics
Venus Remedies Ltd’s financial health underpins its market performance. The company is net-debt free, with an average net debt to equity ratio of -0.14, reflecting a strong balance sheet and minimal leverage. Interest coverage remains robust at 50.94 times, indicating ample capacity to service debt obligations.
Operating profit has grown at an impressive annual rate of 45.72%, while net profit surged by 126.19% in the most recent quarter ending March 2026. The company has reported positive results for six consecutive quarters, with quarterly net sales reaching a record Rs.259.40 crores and PBDIT hitting Rs.63.42 crores, both all-time highs.
Return on Capital Employed (ROCE) for the half-year period stands at a high of 19.85%, while Return on Equity (ROE) is recorded at 15.5%, indicating efficient utilisation of capital and shareholder funds. The company’s Price to Book Value ratio of 3.46x suggests a premium valuation relative to book value, consistent with its growth profile.
Valuation and Market Capitalisation
Venus Remedies Ltd is classified as a micro-cap company, with a Price to Earnings (P/E) ratio of 22x based on trailing twelve months earnings. The EV/EBITDA multiple stands at 14.96x, and the EV/EBIT ratio is 18.12x, reflecting market expectations of continued profitability. The PEG ratio of 0.13x indicates that the stock’s price growth is well supported by earnings growth, suggesting an attractive valuation relative to its earnings momentum.
Dividend payout remains modest, with the latest dividend declared at Rs.3 per share, although the dividend yield is not available. The company’s ex-dividend date dates back to 2013, indicating a focus on reinvestment and growth.
Institutional Participation and Market Interest
Institutional investors have increased their stake in Venus Remedies Ltd by 0.72% over the previous quarter, collectively holding 4% of the company’s shares. This growing institutional interest reflects confidence in the company’s fundamentals and long-term prospects.
Quality Assessment and Growth Trends
The company’s overall quality grade is assessed as average, with strong capital structure and good growth metrics. Management risk is considered average, while the company maintains a low debt profile and no promoter share pledging. Sales growth over five years is recorded at 7.02%, with EBIT growth at 45.72%, underscoring operational expansion.
Tax ratio stands at 23.37%, and the company maintains a zero dividend payout ratio, indicating retained earnings are likely being channelled into growth initiatives. The average Return on Capital Employed over time is 9.53%, with an average ROE of 8.61%, reflecting steady but moderate returns on investment.
Recent Quarterly Highlights
The latest quarterly results for March 2026 demonstrate the company’s peak performance levels. Operating profit to net sales ratio reached 24.45%, the highest recorded, while profit before tax excluding other income stood at Rs.56.66 crores. Earnings per share for the quarter were Rs.35.53, marking a new high.
Cash and cash equivalents were noted as the lowest at Rs.29.61 crores for the half-year, a factor to monitor in the context of liquidity management.
Delivery Volumes and Trading Activity
Trading volumes have shown a marked increase, with a 1-month delivery volume change of 97.05% and a 1-day delivery change of 27.6% compared to the 5-day average. On 11 June 2026, delivery volume reached 1.28 lakh shares, representing 56.23% of total volume, indicating heightened market activity ahead of the all-time high.
Conclusion
Venus Remedies Ltd’s ascent to an all-time high of Rs.1799 on 12 June 2026 is a testament to its sustained financial growth, strong operational performance, and favourable market positioning within the Pharmaceuticals & Biotechnology sector. The company’s robust earnings growth, net-debt free status, and consistent quarterly results have underpinned this milestone. Supported by positive technical indicators and increasing institutional participation, Venus Remedies Ltd has firmly established itself as a noteworthy performer in the micro-cap segment.
